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Executive Summary 
1. This Rapid Evidence Assessment (REA) set out to determine the nature and extent of 
the international research evidence on current responses to end of life care for people 
with substance problems. 
2. There is a dearth of evidence on this issue and no body of evidence that specifically 
identifies effective interventions, responses, or models of practice. 
3. The REA, therefore, refocussed on a broader scoping of the evidence and producing a 
systematic map of the evidence available, the themes and implications for practice, 
and future research. 
4. A final sample of 60 papers was included in the review, 32 of which reported empirical 
research. Of the 32 empirical papers, quality assessment indicated that only nine were 
of high quality, 18 were of moderate quality and five were of low quality. 
5. Most of the papers identified came from North American countries and to a lesser 
extent, Europe and Australia. Only eight were UK based. 
6. More than two thirds of the papers were quantitative in approach. Only 11 papers 
(34.3%) were qualitative. 
7. The majority of papers focussed on some aspect of pain management and prescribing 
practice where there are, or have been, substance problems. Most of these focussed 
on people with cancer diagnoses. 
8. A small body of work focussed on particular groups of people, primarily homeless 
people. 
9. Six papers focussed on alcohol use among people with cancer diagnoses. 
10. There were some common recommendations relating to safe and effective pain 
management strategies, harm reduction strategies and the acknowledgement of 
complex comorbidities among this group of people. 
11. For pain management, screening tools and active monitoring (urine testing, written 
agreements) of people using substances were most commonly recommended 
responses. Clinicians talking to people about their substance use and being aware of 
harm reduction approaches were also recommended. 
12. Recommendations for supporting homeless substance users at the end of lives 
included the provision of alcohol and care in shelter environments, patient contracts, 
safety plans, supervised drug consumption and advance directives. 
13. The alcohol-related papers highlighted the need for an awareness of alcohol 
withdrawal at end of life and the need for routine alcohol assessment among patients 
in palliative care settings. 
14. Common challenges for care providers working with alcohol again highlighted 
concerns about safe and effective pain management. They also highlighted the 
“lifestyle factors” that are associated with substance use and which raise 
professionals’ anxieties about difficult behaviour to manage. 
15. The literature also highlighted the under-utilisation of preventative or primary care 
services by this group of people, the need for empathic communication by 
professionals, and a flexible service response.  
 5 
 
Rapid Evidence Assessment: End of life 
care and substance use  
 
This report presents the findings of a Rapid Evidence Assessment (REA) on the subject of 
end of life care for people with alcohol and other drug problems. It forms one part of a 
wider, six strand programme of research exploring this topic. The other strands are: 
 
• examining how many people with substance-related chronic or terminal illness are 
receiving, or in need of, end of life care in the UK.  
• exploring how people with substance use problems, past and present, experience end of 
life care.  
• exploring the experiences of family members, friends and carers supporting a relative 
with both problems.  
• determining the challenges and opportunities professionals face supporting people with 
substance problems and chronic or terminal illness.  
• key informant interviews to explore the context of substance use and end of life care in 
the UK. 
 
Section 1 - Background 
 
In the last two decades there have been a number of changes evident among the population 
whose use of substances, be they alcohol or other drugs, is problematic.  The most notable 
changes are: 
 
• an increase in the numbers of older drugs users and a resultant rise in rates of death 
from non-drug related conditions (Beynon, 2010),  
• the increase in alcohol-related morbidity and mortality among older users (Kaplan 
et al. 2012), and  
• the emergence and increasing use of  New Psychoactive Substances (NPS - 
previously known as Legal Highs). 
 
The first of these changes, the increase in older drugs users may be due, in part, to the 
transformation in approaches to treatment for illicit opiate users in the 1990’s (McKeganey 
2006) and, specifically, the widening of access to methadone prescription (Clausen 2008, 
Clausen et al. 2009). This expansion in access has meant that growing numbers of current 
and previous substance users now survive long enough to die of the sorts of conditions 
more commonly found in deprived cohorts of the wider population (Corkery 2008; Beynon 
et al. 2010). Alternative explanations are that individuals are continuing to use for longer or 
starting drug use later in life. Regardless of causation, there is evidence of an expansion in 
the numbers of older drugs users known to treatment agencies in the UK (Beynon et al. 
2010; Beynon 2010). Further, changes in life expectancy in the general population leading to 
a pattern of population ageing is likely to be mirrored in the smaller population of substance 
users.  
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Prior to these changes, substance users had disproportionately died from overdoses 
(accidental or deliberate), violence, accidents and disease directly associated with either 
substance or route of administration such as HIV, liver disease and bacterial infections 
(Gibson et al. 2008). The shifts in harm reduction and treatment policies means that older 
substance users (over the age of 40) are now more likely to die of a non-drug related cause 
than users under the age of 40 (Stenbacka et al. 2008, Benyon et al. 2010). Substance users, 
however, are more likely to die at an earlier age than the general population and have 
patterns of disease and morbidity that reflect the impact of substance use or the traumatic 
life experiences more frequently encountered in this group (Beynon et al. 2009, Beynon et 
al. 2010).  
 
The second of these changes is the increasing rate of alcohol-related morbidity and 
mortality connected to chronic and acute alcohol difficulties (Shield et al. 2014, Chang et al. 
2008, Taylor et al. 2010). This is a more complex picture with highest consumption among 
more affluent cohorts of the population (Office for National Statistics, 2017) but the highest 
rates of alcohol-related problems amongst the least affluent (Erskine et al. 2010). Substance 
problems have been associated with increased cancer risk, for example, an increase of 7-
19% for the development of oral cancer associated with alcohol consumption (Petti 2009). 
There is strong evidence that alcohol causes cancers of the oropharynx, larynx, oesophagus, 
liver, colon, rectum and breast (Connor 2016). Excessive alcohol consumption is linked to a 
number of other chronic and potentially end of life conditions, including cardiovascular 
disease and liver cirrhosis (Rehm et al 2009). Ratib et al. (2014) suggest there has been a 
50.6% increase in cirrhosis in England between 1998-2009 and that it is more common in 
younger men and women (this includes both alcohol-related and non-alcohol-related liver 
disease).  
 
The final set of changes is the increase in the use of New Psychoactive Substances (NPS). 
Some of the more immediate consequences of NPS use are apparent in the prisons system 
and in admissions to hospital accident and emergency departments for acute intoxication 
(Ralphs et al. 2017, Liakoni et al. 2016) but what the longer-term impacts on mortality and 
morbidity might be are not yet understood. 
 
For the general population, while life expectancy has been increasing, so too has the 
number of years spent at the end of life living with disability and ill-health (Bell and Marmot 
2017). This has led to a growth in the numbers of deaths which can be anticipated and 
which are likely to require palliative and end of life care (Etkind et al. 2017). However, little 
is known about the nature and extent of need for such care by substance using populations 
or how well services are equipped to work with the people with problematic substance use. 
The wider programme of research, of which this REA is part, sets out to fill this gap in 
knowledge. Specifically, this REA focussed on determining what is already known and 
identifying gaps in the evidence base.  
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Section 2 - Methodology  
 
This strand of the research programme exploring end of life care for people with substance 
problems set out to answer the following research question: 
 
What does the existing international research and wider literature tell us 
about current responses to end of life care for people with substance 
problems?  
 
The question focussed initially on care responses and was broken down further into the 
following aims: 
 
1. to explore and document the evidence base that already exists on responses to end 
of life care for people with substance problems,  
2. to identify gaps in the evidence relating to focus and methodology,  
3. to identify examples of good practice, and  
4. to highlight future directions for research.  
 
A Rapid Evidence Assessment (REA) methodology was identified as the most appropriate 
research tool to use. The UK Government defines REAs as providing “… a more structured 
and rigorous search and quality assessment of the evidence than a literature review” but 
one that has narrower parameters and is not “as exhaustive as a systematic review” 
(Department for International Development (DFID), 2017: online). Thus, REAs stem from 
Systematic Review methodology which traditionally focus on interventions and whether or 
not they work using experimental or quasi-experimental research design. By contrast, REAs 
are used to: 
 
• gain an overview of the density and quality of evidence on a particular issue. 
• support programming decisions by providing evidence on key topics. 
• support the commissioning of further research by identifying evidence gaps. 
(DFID, 2017: online) 
 
These uses of REA outputs clearly spoke to the research aims while its methodology enabled 
a more rapid evidence review to inform other project strands as appropriate.  Further, given 
that a REA is conducted within a shorter time-frame than a Systematic Review, a 
methodology was needed that, while timely, retained the key systematic review 
characteristics of transparency, replicability and comprehensiveness (Government Social 
Research and EPPI Centre, 2009; Galvani & Forrester, 2011; GSR, 2013).  
 
The Government Social Research Framework (GSR) set out a 10-step framework for 
conducting REAs (GSR, 2013): 
 
1. Formulating the REA questions. 
2. Conceptual framework. 
3. Writing a protocol. 
4. Defining inclusion/exclusion criteria. 
5. Search strategy. 
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6. Data collection. 
7. Screening and selecting studies. 
8. Assessing quality and relevance of studies – non-impact questions. 
9. Synthesis of findings. 
10. Communicating findings. 
 
2.1  Formulating the REA questions 
 
The questions for this REA were what the GSR refers to as ‘non-impact’ questions (GSR, 
2013). Given the breadth of our main research question and the perceived lack of research 
in this area, impact questions which focussed on whether a particular type of care response 
was effective were not appropriate. Thus, non-impact questions included a range of 
questions which underpinned the six strands of the research. Table 1, below, sets out the 
key research questions the category or categories of non-impact question addressed: 
 
Table 1: Key research questions and type of non-impact question 
 
REA Question Type of non-impact 
question (GSR, 2013) 
What is the prevalence and incidence of palliative/end of life 
care and co-existing substance use 
Correlation question 
What are the experiences of people receiving interventions 
where there is concurrent alcohol or other drug use and co-
existing palliative or end of life care conditions  
‘Needs’/Process/Attitude/ 
Implementation 
questions  
What are the clinical/practice challenges for professionals 
supporting people using alcohol or other drugs with co-
existing palliative or end of life care conditions  
Implementation/Attitude 
questions 
What are the experiences of family members, friends and 
carers of people receiving interventions where there is 
concurrent alcohol or other drug use and co-existing 
palliative or end of life care conditions  
‘Needs’/Process/Attitude/ 
Implementation 
questions 
What good practice models and care pathways exist for 
people with co-existing substance use and end of life 
conditions, and their families, friends, carers 
Implementation question 
 
Our REA questions were broader in scope than some REA questions would be traditionally 
due to a) needing to explore what evidence existed and b) not being focussed on specific 
interventions as systematic reviews usually are. Our starting point was determining if there 
were any interventions for this group. In a new area of research and practice, such narrow 
focus would have resulted in few, if any, findings.  
 
As the review progressed, the lack of a cohesive body of work to answer the research 
questions indicated that a combination of an REA and systematic mapping methodology 
(Clapton et al. 2009) would be most beneficial. This review still considered these 5 key 
research questions but a dearth of evidence prevented a more nuanced approach in 
exploring the sub categories articulated in the original key research questions. 
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Systematic maps aim to describe the existing literature, and gaps in the literature, in a broad 
topic area, and the literature quality and content can be analysed in depth or more 
superficially as appropriate to individual projects. (Clapton et al. 2009: 11) 
 
Thus, the review was conducted with the rigour of planning and approach of an REA. 
However, as a result of our experience conducting the REA, and the diversity of the 
literature found, it also encompassed systematic mapping of the review’s findings (see page 
16). 
 
2.2  Conceptual framework 
 
Within the literature, the definitions of palliative care and end of life care are vague and ill-
defined with authors often interchanging between the two terms without delineation. For 
this REA, we examined the existing theoretical debates and sought advice from experts in 
the field.  We based the definition of palliative care on a combination of World Health 
Organisation (WHO) guidelines and a final sentence from European Association of Palliative 
Care (EAPC) definition. However, we also strengthened the definition with the inclusion of 
family members, carers and friends. Our definition for palliative care is as follows:  
 
Palliative care is an approach that improves the quality of life of patients 
and service users facing the problems associated with life-threatening 
illness, through the prevention and relief of suffering by means of early 
identification and assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual. It also provides care to family 
members, friends and carers of patients and service users to recognise 
their need for support in their own right and as well as to support them to 
care for their relative or loved one. Palliative care affirms life and regards 
dying as a normal process; it neither hastens nor postpones death. It sets 
out to preserve the best possible quality of life until death. 
 
End of life care is difficult to define since recognising dying is hard to assess or acknowledge 
with many chronic diseases. For this REA our end of life definition remains similar to the 
palliative care definition but a time scale of the last 12 months of life is added. This is in 
keeping with the General Medical Council’s definition of the end of life (2010) which refers 
to patients ‘approaching the end of life’ when they are likely to die within the next 12 
months. This includes patients whose death is imminent (expected within a few hours or 
days) and those with, (a) advanced, progressive, incurable conditions, (b) general frailty and 
co-existing conditions that mean they are expected to die within 12 months, (c) existing 
conditions if they are at risk of dying from a sudden acute crisis in their condition and (d) 
life-threatening acute conditions caused by sudden catastrophic events.   
 
Substance use was defined as problematic alcohol or other drug use, current or previous, 
prescribed or illicit, while receiving palliative or end of life care.  
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2.3  Protocol 
 
This REA was an iterative review and the protocols for the initial five searches that were 
conducted are detailed in Appendix 1 of the REA supplementary appendices document. 
They set out the original protocols for the review. However, the search strategies were 
adapted as the REA proceeded due to the very limited relevant data generated by the initial 
protocols. This approach allowed us to refine the questions and focus once the review was 
underway which is one of the features of an iterative, as opposed to an a priori, review.   
 
Three broad groups of evidence were relevant: 
 
1. existing research on palliative and end of life care  
2. existing research on substance use  
3. the wider health and social care literature, policy and practice documents. 
 
The search protocol needed to ensure these bodies of evidence were included. Common to 
all five searches, (detailed in Appendix 1 of the supplementary appendices document) were 
the databases, additional sources and fields used (see Table 2 below). 
 
Table 2 – Search fields, databases and other sources 
 
Search within 
fields 
keywords/ subject terms 
abstract 
Databases Amed, Psycharticles, Ovid, Ageinfo, MedLine, Ebscohost, ASSIA, Social 
Care Online, Web of Knowledge (including Social Science Citations 
Index), Web of Science, SSCI, Samsha, NIAAA,  
 
The search terms obviously differed across the searches according to their particular focus, 
for example, families of people with substance problems or prevalence and incidence. 
Common to all five searches were terms relating to end of life, palliative care and substance 
use (see Table 3 below): 
 
Table 3 – Search terms common to all strands 
 
Key search 
terms: 
1. alcohol* or drink* or drug* or substance or addict* AND 
2. palliative care or end of life care or dying 
 
Studies reviewed were published in peer-reviewed journals between 1st January 2004-1st 
August 2016. The rationale for the starting date parameter of 2004 was the publication of 
key reports concerning end of life and palliative care that year (NICE 2004, Gysels and 
Higginson 2004). An additional limiter was that the papers were written in English. 
 
After conducting the five separate searches there were limited data generated from the 
search terms. Specific, well-defined areas that were initially identified could not be found 
within the literature. Subsequently, the search terms were broadened to capture all the 
literature within this field (see Table 4 below).  
 
 
Table 4 - Final search terms 
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Key search 
terms: 
1. end of life, palliative, dying, death, life limiting, life threatening 
2. drug misuse/abuse/use, substance use/misuse/abuse, medication 
use or abuse, alcohol 
 
Inclusion and exclusion criteria were drawn up for each search and applied throughout the 
screening process; title, abstract, and full text. We also excluded tobacco-related studies. 
Excluded papers were coded A-E (see coding table below in Table 5).  
 
Table 5 – Coding table 
 
A Is not related to palliative or end of life care  
B Is not related to substance use 
C  Is not related to palliative or end of life care nor substance use 
D Not about pathways; not about professional practice concerns; not about family 
and social networks; not about impact or considerations. 
 
E Does not meet the above, but is of interest so placed in separate folder. 
 
For ‘borderline’ papers, further discussion took place between two reviewers as to whether 
the paper should be included in the review. If any disagreement remained, the papers were 
reviewed by a third member of the research team who had the casting vote. There was no 
hand searching of references within this REA. Two researchers subsequently read all the 
included papers to identify initial themes or topic areas. 
 
2.4  Data extraction and synthesis 
 
As outlined previously, given the dearth of intervention studies and the limited literature 
found through the initial searching, a systematic mapping approach was adopted. This 
facilitated the development of a visual map of the existing literature on the broad topic of 
substance use and end of life care. It also allowed categorisation of the existing evidence in 
a number of ways, including its methodology, focus and country of origin (see Appendix 2 of 
the supplementary appendices document).  
 
Textual narrative synthesis (Barnett-Page & Thomas 2009) was used to explore any 
similarities, differences and relationships between papers. This was facilitated by a three-
step process (Lucas et al. 2007) including: 
 
1) Study grouping; in which studies belonging to each of the sub-groups were identified 
with two researchers independently categorising and theming the papers. If there 
was any disagreement, a third researcher reviewed the paper.  
2) Study commentaries were produced in an excel file to summarise key aspects of the 
papers in relation to the subgroup within which they were included. This included 
both key findings and/or recommendations that address the aims of this REA. In 
terms of quality control each commentary was reviewed by a second researcher 
independently to assess the summary in relation to the original paper.  
3) Sub-group synthesis was then produced, for example examining aspects of good 
practice in palliative care within the context of cancer and substance misuse. 
 12 
 
 
2.5  Assessing quality and relevance 
 
The quality of the individual studies was assessed based on six principles derived from DFID 
(2014) guidance (Table 6). 
 
Table 6 - Criteria used to assess individual empirical studies  
 
Principles of quality Associated questions 
Conceptual framing Does the study acknowledge existing research? 
 Does the study construct a conceptual framework? 
 Does the study pose a research question or outline a hypothesis? 
Transparency Does the study present or link to the raw data it analyses? 
 What is the geography/context in which the study was conducted? 
 Does the study declare sources of support/funding? 
Appropriateness Does the study identify a research design? 
 Does the study identify a research method? 
 Does the study demonstrate why the chosen design and method 
are well suited to the research question? 
Cultural sensitivity Does the study explicitly consider any context-specific cultural 
factors that may bias the analysis/findings? 
Validity To what extent does the study demonstrate measurement 
validity? 
 To what extent is the study internally valid? 
 To what extent is the study externally valid? 
 To what extent is the study ecologically valid? 
 To what extent are the measures used in the study internally 
reliable? 
 To what extent are the findings likely to be sensitive/changeable 
depending on the analytical technique used? 
Cogency Does the author ‘signpost’ the reader throughout? 
 To what extent does the author consider the study’s limitations 
and/or alternative interpretations of the analysis? 
 Are the conclusions clearly based on the study’s results? 
 Is the study dealing with an on-going or completed intervention? 
 Is it part of a wider initiative or is it self-contained? 
 
A seventh criteria that is commonly used is reliability. It describes how robust results are in 
the sense of being able to replicate stable results. This was not used as it was found not to 
be assessable for most of the studies. A further criterion, relevance, was taken into account 
in the literature search process that produced the evidence base, but was not included as a 
factor in the quality assessment. The empirical studies in the evidence base were scored on 
all six criteria (listed in Table 6 above) on a three-point scale reflecting the extent to which 
the studies followed good research practice: 
  
 
▪ 3 = no concerns;  
▪ 2 = some minor concerns;  
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▪ 1 = major concerns.  
 
This results in a score ranging from 6 to 18 for each study. Studies were then assigned a 
quality category of high, moderate or low, based on their score (Table 7). 
 
Table 7: Quality abbreviations 
 
Quality score Symbol Definition 
High (14–18)  ↑ Comprehensively addresses the majority 
of the principles of quality. 
Moderate (10-13) → Some deficiencies in attention to the 
principles of quality. 
Low (6-9) ↓ Major deficiencies in attention to the 
principles of quality. 
 
All empirical studies (n=32) referred to in this REA were scored according to these criteria.  
Table 8 summarises the evidence base found for this REA in terms of types of study and 
quality. The quality indicator for each individual empirical study is highlighted in Appendix 2 
of the supplementary appendices document.  
 
Table 8: Quality ratings of empirical literature 
   
Study quality Symbol Type of study Number % of all studies 
High (14-18) ↑ Primary 
Secondary 
9 28.1% 
Moderate (10-
13) 
→ Primary 
Secondary 
18 56.2% 
Low (6-9) ↓ Primary 
Secondary 
5 15.6% 
Total   32 100% 
 
It is important to note that a low or moderate ‘quality’ rating does not imply that a study 
was poorly designed or executed, and does not suggest that its conclusions are incorrect or 
unreliable. It can simply mean that the report of the study did not fully explain its design or 
methods. 
 
2.6  Limitations of methodology 
 
The decision to set the cut-off date at 2004 meant that some studies prior to this date were 
not reviewed and it is not possible to know how many would have met our inclusion criteria. 
Nevertheless, agreeing and adhering to a date limiter is an accepted feature of REA’s as is 
the need to set limits on the retrieval of full texts (Government Social Research and EPPI 
Centres 2009). Within substance use and palliative/end of life care there are very large 
associated literatures such as multiple morbidities, problems with chronically ill substance 
users and issues around cause of death and patterns of particular conditions (for example, 
head and neck cancers). Capturing the nuances of end of life and substance use within these 
competing contexts is challenging. For instance, within this REA there appears to be limited 
published literature relating to alcohol and palliative and end of life issues. There is likely to 
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have been more literature relating to alcohol had search terms such as liver disease been 
included. We are aware that other passing references to substance use and end of life care 
are buried in wider literature. This is not a limitation in the searches undertaken as much as 
a limitation in systematic review methodologies, particularly where the literature is not well 
developed. Alternately, complex associations and interactions mean relevant issues (such as 
substance use and end of life) are not explicitly identified in a piece of research. 
 
A further limitation related to the challenges of comprehensively identifying relevant 
material from the grey literature. This is primarily attributable to the very large volume of 
hits associated with each of our search terms separately and the lack of time within an REA 
to mine many thousands of hits for relevant data. As a result, the grey literature was 
excluded from this review and this should be an area of focus for future research. 
 
A final significant limitation is that the papers were predominately from the USA, Canada 
and to a lesser extent, UK, Europe and Australia. Clearly, there is likely to be significant 
diversity of both substance use and end of life practices across the globe. Papers from 
outside this domain are present but are few in number. This is an important finding in its 
own right, however, it creates difficulties in interpreting the applicability of results since 
factors such as service provision and broader social systems for delivering help in the 
context of end of life/palliative care and substance use may differ in a global context.   
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Section 3 - Findings 
 
The final search of peer reviewed articles resulted in 4384 hits. After the first screening of 
titles, the inclusion and exclusion criteria were applied at abstract and full text reading 
stages (see Figure 3.1 below) resulting in a final sample of 60 papers (Appendix A in this 
report provides a reference list of all 60 papers).  
 
Figure 3.1 – Review process from initial search to final sample of papers 
 
 
There were 60 papers generated from the search after applying the inclusion and exclusion 
criteria. They were, however, extremely diverse in methodology, focus and audience. The 
systematic map below (Figure 3.2) illustrates the range of evidence found among the 60 
papers. 
 
  
Total number of hits
n= 4384
First screening of 
titles 
Total removed
n= 4232
Second screening of 
abstracts
Total removed
n = 82
Not about substance use n =  25
Not about EOL care n = 36
Neither about sub use or EOL  n= 21
Full text reading
Total removed
n = 10
Not about substance use n = 6
Not about EOL care n = 2
Neither about sub use or EOL n= 2
Final sample for 
inclusion
n = 60
Not about substance use or End of Life 
(EOL)
n= 4232
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Figure 3.2 - Systematic Map: Substance Use and End of Life Care 
 
 
 
 
1.  
 
Date: (n = 60) 
(date parameters 2004-2016)
2004-2008 (n = 12) 20%
2009- 2012 (n = 23)  38.3%
2013-2016  (n = 25) 41.6%
Country (n = 60)
USA   (n = 34) 56.7% 
Canada (n = 12) 21.6%
UK   (n = 9)  13.3%
Australia   (n = 3)  5%
Italy  (n = 1)  1.6%
Sweden (n = 1) 1.6%
Type of Publication (n = 60)
Journal Article   (n = 58)  96.7%
Book chapter  (n = 2)  3.2%
Content (n = 60)
Pain management  (n = 25) 41.6%
Homelessness and marginalised 
groups  (n =24) 40%
Alcohol related  (n = 6)  10%
Other (n = 5) 8.3%
Empirical/ Unempirical (n = 60)
Empirical  (n = 32)  53.3%
Unempirical  (n = 28)  46.6%
Qualitative/ Quantitative/ Mixed 
Methods (n = 32)
Qualitative  (n = 11)  34.3%
Quantitative  (n = 21) 65.6% 
Mixed  (n = 0) 
Type of Study (n = 32)
EMPIRICAL
Cross sectional  (n = 6)  18.7%
Focus groups  (n = 2) 6.2 %
Interview  (n = 9)  28.1%
Survey (n =6) 18.7%
Retrospective Chart review (RCR) (n = 
9) 28.1%
Type of Study (cont.)
UNEMPIRICAL (n= 28)
•Case study  (n =10)  35.7%
•Description of practice  (n = 8)  28.5%
•Literature review  (n = 5) 17.8%
•Systematic review (n=3) 10.7%
•Book chapter (n=2) 7.1%
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The majority of papers found were published in the last decade and were North American 
(USA or Canadian) in origin. Just over half were based on empirical research of some kind 
with more quantitative data than qualitative data presented.  The greater number of journal 
articles compared to other sources was a result of our search strategy which focussed on 
published research. As with other new areas of research, for example sight loss and 
substance use (Galvani et al. 2016), there were a number of clinical case studies presented 
in the literature.  
 
As the systematic map shows, the topic focus of the evidence could be grouped around 
three main themes: pain management (n=25), homeless and marginalised populations 
(n=24) and alcohol-related papers (n=6). In addition, there were five remaining papers 
which were diverse in focus and methodology. In terms of these three main categories, 
there were some overlap within the papers, for example, pain management with alcohol 
use or within homeless populations, however, the focus of the papers remained 
predominately within the categories assigned.  
 
 
3.1  Gaps in the evidence 
 
In addition to what is there, systematic maps helpfully highlight significant gaps in the 
evidence base. Very little research has been done in the UK on co-existing substance use 
and end of life care with only eight pieces of UK literature identified. Most published 
research in this area has been generated in North America. This review was limited to 
English language literature so it is possible that some additional literature is available in 
other languages. The dearth of literature on this topic, however, suggests that, if there was 
additional literature, this would not be a large body of work.  
 
The systematic map also shows that less than two thirds of the literature identified was 
empirical work with the remainder descriptive papers, book chapters, single case studies, or 
reviews of literature. It also needs to be noted that several articles by two authors appeared 
to be drawn from the same research project (McNeil and Guirguis-Younger 2011, McNeil et 
al. 2012a, McNeil et al. 2012b, Song et al. 2006a and Song et al. 2006b) thus the number of 
research studies documented in the evidence found does not represent the number of 
studies undertaken. 
 
The existing evidence is also dominated by quantitative research with approximately one 
third of it using qualitative methods. This means there is limited research evidence of the 
lived experiences of those who live and work with co-existing substance use and end of life 
or palliative care needs. There were no identified papers related specifically to family or 
carers/supporters of people with substance problems at the end of life. Within all the 
empirical papers (either quantitative or qualitative) there were only eight papers that 
documented professionals’ perspectives, three that mentioned service user perspectives of 
family members and carers’ involvement, and seven that documented service users’ 
perspective or those with experience of receiving services previously. 
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Finally, the map shows a narrow and limited topic focus of the evidence to date1. The 
themes identified are drawn from a very diverse literature in both focus and methodology 
(see Appendix A below). However, the majority focus on some aspects of pain management 
and prescribing practice where there are, or have been, substance problems and 
predominantly among people with cancer diagnoses; a small body of work focusses on 
particular groups of people, primarily homeless people; several papers have an alcohol-
specific focus often in relation to cancer care.  
 
There were no intervention or evaluation studies and no practice models that were 
underpinned by a robust evidence base relating to substance use and end of life care. There 
was no consensus about what constitutes good practice although there were common 
underlining recommendations particularly relating to a) pain management strategies 
involving screening and monitoring and b) harm reduction strategies for homeless/ 
marginalised populations in addressing (and acknowledging) the complex comorbidities in 
patients with substance problems. There were no studies relating to New Psychoactive 
Substance use (NPS) and its impact on end of life care. There were only four papers 
examining older drug users (Beynon et al. 2010a, 2010b, Roe et al.  2010 and Williams et al. 
2014). Two papers examined changing mortality of drug users in treatment (Beynon et al. 
2010a, 2010b), the third explored the experiences of drug use and ageing (Roe et al. 2010) 
and the fourth focused on older jail inmates (Williams et al 2014).  
 
In spite of the dearth of research in this area, and the lack of quality of much of the existing 
evidence, the following section offers greater detail on the results of this REA taking each 
thematic group in turn. 
 
 
3.2  Thematic groups 
 
To recap, the evidence fell into three thematic groups with seven papers categorised in a 
Miscellaneous category. The three themes were: Pain Management, Homelessness and 
Marginalised Populations, and Alcohol-Related evidence. (Details of the all these papers can 
be found in Appendix 2 of the supplementary appendices document. The reference list for 
these papers are listed in Appendix A to this report).  
 
3.2.1  Pain Management (n=25) 
Pain management was marginally the largest category to emerge from the peer-reviewed 
literature. The majority (n=23) were from the USA with the other single papers from Canada 
and the UK. The studies ranged from clinical chart/note reviews (Barclays et al. 2014, 
Childers et al. 2015, Kwon et al. 2013, 2015, Rowley et al. 2011), to small scale case study 
reviews (Arthur et al. 2016, Burton-MacLeod et al. 2008, Farnham 2012, Kirsh and Passik 
2006, Koyyalagunta et al. 2011, Kutzen 2004, Walsh and Broglio 2010). There was also one 
integrated literature review (Carmichael et al. 2016) examining assessment and risk in 
relation to opioid misuse within cancer care and two systematic reviews (Chou et al. 2009, 
Taveros and Chuang 2016). Chou et al. (2009) examined opioid misuse in the context on 
non-cancer chronic pain, and Taveros and Chuang (2016) examined pain management 
                                                     
1 We offer a note of caution, however, in that the thematic groupings are our own and others may group them 
differently. 
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strategies for people on methadone maintenance therapy. Five studies used structured 
questionnaires as part of their approach (Williams et al. 2014, Tan et al. 2014, Childers and 
Arnold 2012, Knowlton et al. 2015, Blackhall et al 2013).  
 
The remaining five studies were discussion papers: 
• Krashin et al. (2012) presented a discussion examining pain where there was co-morbid 
substance use and presented guidelines in which he suggested all pain patients should 
be routinely assessed via screening tools, urine drug tests and treatment agreements in 
the provision of safe, effective pain care.  
• A second paper by the same author, also based on expert opinion, offered a further 
exploration of issues related to risk assessment; including comprehensive history taking 
to include history of substance misuse, family history of substance misuse, history of 
childhood abuse and psychiatric co-morbidities. This is within a palliative care context 
and the authors again suggest the importance of using a validated assessment tool, such 
as CAGE, (which is a screening tool for problem alcohol use) (Krashin et al. 2015).  
• Passik et al. (2009) explored and discussed opioid misuse in cancer care. Screening for, 
an assessment of, aberrant drug taking behaviour was important as was screening for 
psychiatric conditions and routine urine testing. 
• Pancari and Baird (2014) presented a discussion paper regarding drug diversion for 
prescription medications within an American context. This relates to people that could 
potentially divert medications including family/carers and health professionals. One of 
the contexts was end of life care and systematic monitoring of patients at risk through 
“home” agreements was encouraged. 
• Riesfield et al. (2009) reviewed guidance from existing published literature and suggests 
recovery programs, treatment, and written opioid agreements are important. He stated 
clinicians need to treat pain aggressively and address anxiety and depression. Clinicians 
also need to monitor these patients closely. 
 
In terms of the populations of interest, the majority of papers (n=13) were within a context 
of pain in cancer care (Arthur et al. 2016, Barclay et al. 2014, Burton-MacLeod et al. 2008, 
Carmichael et al. 2016, Childers et al. 2015, Kirsh and Passik 2006, Koyyalagunta et al. 2011, 
Kwon et al. 2013, 2015, Passik et al. 2009, Rowley et al. 2011, Taveros and Chuang 2016 and 
Walsh and Broglio 2010). One study examined pain in prison populations (Williams et al. 
2014) whilst Kutzen (2004) and Knowlton et al. (2015) focused on pain in the context of HIV 
disease with Koyyalagunta et al. (2011) also exploring a subset of HIV patients.  
 
The other studies examined substance misuse from a general palliative care context 
(Childers and Arnold 2012, Farnham 2012, Krashin et al. 2015, Tan et al. 2014, Pancari and 
Baird 2014, Riesfield et al. 2009) with two covering chronic non-cancer pain (Chou et al. 
2009, Krashin et al. 2012). A number of papers acknowledged both the complexity of pain 
management and persistent issues of under-treatment of patients with substance misuse 
issues (Farnham 2012, Koyyalagunta et al. 2011, Krashin et al. 2015, Kwon et al. 2015, Lum 
2003, Passik et al. 2009, Rowley et al. 2011, Walsh and Broglio 2010, Williams et al. 2014). 
This led most papers to emphasise the need for comprehensive assessment as an essential 
step in managing pain in people using substances, requiring active engagement from the 
clinician.   
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3.2.1i  Screening tools and processes 
In terms of recommendations, screening for substance misuse was a central theme, 
particularly within the papers examining cancer care (Barclay et al. 2014, Burton-MacLeod 
et al. 2008, Carmichael et al. 2016, Childers et al. 2015, Kirsh and Passik 2006, Koyyalagunta 
et al. 2011, Kwon et al. 2013, Passik et al. 2009, Walsh and Broglio 2010). This theme 
extended to papers examining non-cancer pain (Chou et al. 2009, Krashin et al. 2012, 
Pancari and Baird 2014, Riesfield et al. 2009) and with general palliative care populations 
(Farnham 2012, Krashin et al. 2015, Tan et al. 2015). Tan et al. (2015) surveyed Palliative 
Medicine Fellowship program directors in the USA and most were aware of the importance 
of screening for substance misuse although 67.6% did not have a written policy. Kutzen 
(2004) focused on pain within HIV disease and this paper focused on using pain assessment 
tools, so screening for pain rather than substance misuse.   
 
There was an emphasis on the need to use validated tools (Arthur et al. 2016, Barclay et al. 
2014, Carmichael et al. 2016, Childers et al. 2015, Farnham 2012, Kirsh and Passik 2006, 
Koyyalagunta et al. 2011, Krashin et al. 2012, 2015, Passik et al. 2009, Walsh and Broglio 
2010) with some papers recommending or using a particular measure to assess substance 
use, for example, SOAPP-R, which assesses potential opioid misuse (Krashin et al. 2015, 
Passik et al. 2009) or CAGE, to screen for alcohol problems (Arthur et al. 2016, Kwon et al. 
2013, 2015). From their systematic review, Chou et al. (2009) recommended the need for 
better screening measures since there was no strong evidence to identify predictors for 
drug-related behaviours. Urine screening was recommended by some papers to identify 
patients with substance use problems (Arthur et al. 2016, Barclay et al. 2014, Childers et al. 
2015, Kirsh and Passik 2006, Krashin et al. 2015, Passik et al. 2009). Some papers recognised 
that psychiatric co-morbidities could lead to “chemical coping” strategies and that 
screening/referral for psychiatric morbidities was an important element of assessment 
(Burton-MacLeod et al. 2008, Kirsh and Passik 2006, Koyyalagunta et al. 2011, Krashin et al. 
2015, Kwon et al. 2015, Passik et al. 2009).  
 
“Chemical coping” was defined in this literature as the potential for patients with a history 
of problematic substance use to use substances in an attempt to control unmanaged pain. 
In relation to cancer, Kwon et al. (2015) commented that substances were used “to cope 
with the various stressful events associated with the diagnosis and management of cancer” 
(pp 693). Kirsh and Passik (2006) also mentioned “pseudo-addiction”; behaviours that are 
misunderstood by health and social care staff as drug seeking (when patients “act out” 
when distressed) rather than originating from poor or inadequate pain control. Kutzen 
(2004) suggested there was a need to distinguish between tolerance, physical dependence, 
and addiction, although did not specify how this can be achieved.     
 
3.2.1ii  Monitoring pain and prescribing 
Active monitoring of patients with identified substance use problems was explored in a 
number of papers. Monitoring activities included pill counting (Arthur et al. 2016, Barclay et 
al. 2014, Carmichael et al. 2016, Farnham 2012, Taveros and Chuang 2016) and enabling 
only a limited supply of medication or prescription monitoring programs (Arthur et al. 2016, 
Barclay et al. 2014, Carmichael et al. 2016, Farnham 2012, Kurtzen 2004, Taveros and 
Chuang 2016). This population may require more frequent outpatient visits (Koyyalagunta et 
al. 2011) with Kirsh and Passik (2006) further suggesting that ongoing prescriptions should 
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be dependent on patient attendance on a 12-step program. Urine testing (including random 
testing) was also recommended for monitoring patients on opioid therapy with a history of 
substance misuse (Arthur et al. 2016, Carmichael et al. 2016, Farnham 2012, Koyyalagunta 
et al. 2011, Krashin et al. 2012, Passik et al. 2009). Some papers suggested written opioid 
agreements with expectations and rules (Burton-MacLeod et al. 2008, Farnham 2012, Kirsh 
and Passik 2006, Koyyalagunta et al. 2011, Krashin et al. 2015, Kutzen 2004, Passik et al. 
2009, Taveros and Chuang 2016).  Some authors also mentioned drug diversion as a 
potential issue for clinical concern (Krashin et al. 2015, Kirsh and Passik 2006, Pancari and 
Baird 2014, Tan et al. 2015). This relates to either the patient selling, or their family/friend 
using or selling, prescribed opiates. They suggest assessing family substance use in order to 
identify risk and monitor accordingly. This requires health professionals to actively monitor 
potential drug diversion within this population.  
 
3.2.2  Homeless and Marginalised Populations (n=24) 
This group of papers focussed on people who are homeless or precariously housed, those 
with mental health difficulties (including a paper, Antoni et al. 2012, looking at the 
experiences of US army veterans), and those with HIV in the context of multiple social 
problems. Three papers addressed marginalised populations more generally (Doukas 2014; 
Dzul-Church et al. 2010; Sulistio and Jackson 2013).  
 
3.2.2i  Homelessness 
The majority of papers in this thematic group focussed on homeless and precariously 
housed people (Hudson 2016, Collier 2011, Dzul-Church et al. 2010, Kusel and Miaskowski 
2006, MacWilliams et al. 2014, McNeil and Guirguis-Younger 2012a, 2012b, McNeil et al. 
2012a, McNeil et al. 2012b, Page et al. 2012, Podymow et al. 2006, Song et al. 2007a, 2007b, 
Webb 2005). Most were qualitative studies conducted in Canada (n=7), with four from the 
USA, one from Australia and two from the UK. Four papers by McNeil and colleagues in 
Canada drew on a single primary piece of qualitative work to examine the needs of 
homeless people, including staff experiences of their needs. They also highlighted some 
areas of good practice based on their data. These included the provision of alcohol in 
shelters and proposals for supervised drug consumption in order to increase engagement 
with palliative care services. The research looked at gaps in services and proposed that 
some of these could be met by shelter-based palliative care. The work of Song et al. (2007a, 
2007b) and Podymow et al. (2006) identified similar issues. Both these authors found that 
end of life advanced directives were very positively perceived by homeless people including 
‘do not attempt cardio-pulmonary resuscitation’ orders.  
 
MacWilliams et al.’s (2014) case study approach identified similar issues but focused on the 
consequent difficulties with compliance in treatment. In particular, they discussed what this 
then meant for pain control and reducing the risks of sudden crisis and deterioration where 
someone is homeless. Kushel and Miaskowski (2006) identified the usefulness of "patient 
contracts" as a means of addressing such difficulties using a case-based approach. The 
remaining papers examining homelessness included one review paper, Hudson (2016) from 
the UK, Webb (2005) who examined seven UK hostel workers’ experiences in relation to 
supporting homeless people at the end of life and a paper by Page et al. (2012) which 
looked at causes of death amongst homeless people in Alberta, Canada. The findings of this 
study showed that most deaths were due to "natural causes"; that is, not the types of death 
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often associated with drug use such as overdoses and suicides. Page et al. (2012) also 
proposed that this meant that the circumstances of death could have been improved by 
more effective delivery of end of life care to homeless persons.    
 
3.2.2ii  Mental health 
Mental ill health arose as a sub-theme in a number of the papers identified in this review. 
However, mental health was identified as a primary issue in a review paper by Miovic and 
Block (2007) looking at psychiatric disorders in advanced cancer, and as a co-existing issue in 
Antoni et al (2012) where it was located amongst the difficulties experienced by US army 
veterans. Depression is known to be associated with chronic and terminal illness and with 
pain, both as a factor in causation and as a consequence of illness. This links with the pain 
literature, where a number of authors suggested screening and referral to secondary mental 
health services (Barclay et al. 2014, Burton-MacLeod et al. 2008, Kirsh and Passik 2006, 
Koyyalagunta et al. 2011, krashin et al. 2015). 
 
3.2.2iii  HIV 
Halman et al. (2014) undertook a retrospective chart review (single institution) from 83 late-
stage HIV patients highlighting substance use co-morbidities of a subset of people dying 
with HIV-related conditions.  Two papers from the USA, Karus et al. (2004) and Morgan and 
Kochan (2008) explored HIV in relation to substance use and end of life and found issues of 
underlying poverty and a lack of sufficient health insurance. HIV disease per se was not seen 
as an issue for end of life care but rather HIV in a cluster of mental health problems 
alongside substance use, the combination of which raises the sorts of issues previously 
highlighted around compliance and pain control.  
 
3.2.2iv  Marginalised populations 
There were four papers addressing what we have termed marginalised populations.  
• Doukas (2014), in a discussion paper, explored whether methadone counsellors in 
Canada were equipped to deal with the multiple morbidities increasingly associated with 
ageing drug users, proposing that training was needed to increase counsellors’ palliative 
and end of life care skills.  
• Dzul-Church et al. (2010) interviewed 20 patients at one hospital in the USA who were 
terminally ill. The issues associated with dying in poverty and with minimal or no health 
insurance were highlighted.  
• Australian authors Sulistio and Jackson (2013), presented a single case study to illustrate 
the complex issues that arose in providing end of life care for a person who had used 
multiple substances and who experienced emotional and social difficulties. They 
propose that this combination of factors is likely to be increasingly evident among 
people presenting to services and will raise powerful challenges for staff. Their case 
study shows how their team addressed these challenges.  
• Mundt-Leach (2016) in a literature review recommended that a discussion is needed 
about what recovery means in the case of addiction at end of life calling for closer 
working relationships between palliative care and addictions services. 
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3.2.4  Alcohol-related (n= 6) 
 
There were six papers identified that had alcohol as a primary focus (Dev et al. 2011; Irwin 
et al. 2005; Kwon et al. 2013b; Mercadante et al. 2015; Poonja et al. 2014 and Webber and 
Davies 2012). 
 
• Dev et al. (2011) undertook a chart review from which 598 patients from the USA 
completed a screening survey to establish the frequency of undiagnosed “alcoholism” in 
patients with advanced cancer who were referred for palliative care, and to explore its 
correlation with alcoholism, tobacco use and use of illegal drugs. These data suggest that 
alcoholism is highly prevalent and frequently under diagnosed in patients with advanced 
cancer.   
• Irwin et al. (2005) reviewed terminal restlessness2 through four illustrative case studies, 
from an Australian perspective, suggesting that alcohol withdrawal may be a 
contributing factor. They recommend universal screening for alcohol misuse in all 
patients with advanced cancer.  
• Mercadante et al. (2015) conducted a prospective prevalence study of rates of 
alcoholism (using the CAGE questionnaire) amongst 443 advanced cancer patients 
admitted to two palliative care settings in Italy. The rates of CAGE-positivity were low in 
this population. Of those CAGE-positive patients, they were more likely to be male and 
younger, independent of diagnosis and performance status. The authors highlight the 
brief alcohol assessment tool CAGE as a useful tool for detecting alcohol problems and 
suggest routine assessment should be introduced within palliative care settings.  
• Poonja et al. (2014) conducted a retrospective study in Canada of 102 consecutive adult 
patients with liver cirrhosis removed from the transplant list or denied treatment. 
Records were assessed to determine access to palliative care. Patients who were 
removed from the waiting list were not often referred for palliative care although many 
had pain and nausea. ‘Do not attempt resuscitation’ (DNAR) orders and goals of care 
were seldom discussed with patients.  
• Webber and Davies (2012) conducted an observational and cross-sectional study 
(n=120) on the prevalence of alcohol disorders in UK patients with advanced cancer and 
found alcohol disorders in this cohort of patients were not associated with the higher 
symptom burden found in other studies. Prevalence of alcohol use disorders was lower 
than in the general UK population.  
• In a retrospective study, Kwon et al. (2013b) examined patients’ notes to explore patient 
characteristics of US cancer patients referred early to palliative care. Early referrals were 
often younger, showed more CAGE positivity, were referred post radiotherapy, 
diagnosed with head and neck cancer, and presented with a greater number of 
symptoms.  
 
Five of the papers examined alcohol use in relation to cancer and one related to liver 
cirrhosis. The prevalence of alcohol use disorders in the advanced cancer population in the 
US has been estimated at 14-38% (Parson et al. 2008, Jenkins 2000). Webber and Davies 
(2012), however, found a rate of 18%; a lower proportion than that in the general 
                                                     
2 Terminal restlessness is a common end of life symptom (Kehl 2004). 
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population. To what extent that reflects different rates in the respective US and UK 
populations is not clear.  
 
Men form the overwhelming majority of problem alcohol users identified in most studies; 
usually by a factor of more that 2:1 and this continues into the palliative/advanced cancer 
population. Problematic alcohol use appears to be more common in younger palliative 
populations (Kwon et al. 2013b). The most frequently used alcohol screening instrument 
documented in the evidence to date appears to be the CAGE questionnaire although others 
are used in addition to, or instead of, CAGE. The papers focussed on screening and concerns 
about "undocumented" alcohol difficulties. This focus on screening for alcohol problems 
among the end of life care population mirrors the concerns identified in the pain literature 
around "chemical coping" (Kwon et al. 2015).  
 
Most studies in this section and in pain management (above) find higher symptom burden 
to be associated with alcohol and other substance use.  This may be due to the well-
documented link between problematic alcohol consumption and head and neck cancers 
(Boffetta and Hashibe 2006) and higher rates of smoking amongst alcohol users (Dev et al. 
2011). Webber & Davies (2011) found that half of the head and neck cancers cases in their 
study screened as positive for high-risk alcohol use using the AUDIT tool. Miovic and Block 
(2007) estimated that 33.6% of those with head and neck cancers in their study met criteria 
for alcohol dependence.  
 
3.2.5  Miscellaneous 
 
Of the five remaining papers, three focussed on drug-related deaths: 
• Beynon et al. (2010a) examined the changing patterns of causes of death amongst 
substance users in the North West of England. They found the median age of death rose 
from 36.46 in 2003-04 to 41.38 in 2007-08 and that causes of death were increasingly 
related to chronic conditions more associated with older age.  
• Stenbacka et al. (2010) reviewed changes in substance-related mortality patterns in 
Sweden.  The average age of death was 47 years - 25-30 years less than the general 
population. Women had lower mortality rates and accidents and suicides were the most 
common causes of death in younger substance users, with cardiovascular disease and 
tumours most common amongst older substance users.  
• Corkery (2008) reviewed classification issues in drug-related deaths (DRD) in the UK and 
found DRDs fall into two broad categories; those directly attributable to drug use 
(overdoses and poisoning) and indirectly attributable, that is, related to drug use such as 
infections and accidents. The author suggests that more attention is given to direct DRDs 
rather than the long-term consequences of drug use.   
 
Two papers looked at older drug users in particular: 
• Roe et al. (2010) undertook qualitative interviews (n=11) with older drugs users who 
used a voluntary drug treatment service and found drug use impacts negatively on 
health and family relationships and support. Many older users lived alone and had 
multiple experiences of loss. 
• Beynon et al. (2010b) reviewed UK patterns of drug use with a focus on older users. 
They found older drug users presented with particular challenges such as interactions 
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between legal and illegal drugs, lack of social support, cognitive impairment and issues 
around managing pain, particularly at end of life. 
 
3.2.6 Summary 
 
In sum, the findings of this REA demonstrated a largely heterogeneous literature, with 
limited empirical work in any specific area of end of life care for people with substance 
problems. In the thematic analysis of these studies, pain management was, marginally, the 
largest category (n=25), followed by homeless and marginalised groups (n=24) and finally, 
alcohol-related papers (n=6). The majority of studies focused exclusively or predominantly 
on cancer populations, including 14 studies within the thematic category of pain 
management and all six of the papers related to the alcohol literature. Within the pain 
literature, six studies were from more general palliative care populations with three related 
to HIV and two to non-cancer chronic pain. There were a small number of miscellaneous 
papers (n=5). In terms of geographical distribution of the published literature, the majority 
of the studies were from North America, (n=46; 76.7%) with the second largest sample from 
Europe (n=11; 18.2%). Only eight papers were from the UK. Therefore, the majority of the 
published literature from this REA is from a narrow geographical area. Within the thematic 
category of homeless and marginalised populations, the studies focused on mental health 
needs, HIV and homelessness and often related to service provider response. This category 
was often represented by studies using qualitative approaches (n=9) and therefore 
exploratory in nature, examining both service user and service provider perspectives.    
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Section 4 - Discussion 
 
This review of the evidence set out to answer the following research question: 
 
What does the existing international research and wider literature tell us 
about current responses to end of life care for people with substance 
problems?  
 
 Our aims were to:  
 
1. explore and document the evidence base that already exists on responses to end of 
life care for people with substance problems,  
2. identify gaps in the evidence relating to focus and methodology,  
3. identify examples of good practice, and  
4. highlight future directions for research.  
 
The evidence base has been presented above (aim 1). What is evident is the lack of research 
on responses and interventions for people with problematic substance use and end of life 
care needs. There is only a small and diverse literature that lacks depth and quality. The 
gaps in the existing evidence are many (aim 2), however, this is not surprising in a newly 
recognised area of practice. Research has yet to respond to the emerging practice needs in a 
significant way. 
 
The third aim was to identify examples of good practice and highlight the challenges, 
obstacles or barriers that services encountered in working with co-existing substance 
problems and end of life care needs (aim 3). In developing the search strategy, search terms 
were included to identify papers that specifically addressed practice. However, despite 
trying a variety of terms, no papers were found. The search strategy field was abstracts and 
but when the final group of papers were read it became clear that there were examples of 
practice and indicators of barriers or challenges embedded in several papers whose main 
focus was in other areas, for example, pain management or homelessness.   
 
Identifying "good" practice clearly involves a measure of judgement as to whether the 
practice described is "good" or "bad". In more well-developed fields, there may be existing 
quality standards which can be used to measure or review practice. However, this is a 
relatively new literature and, as detailed above, a diverse and heterogeneous one. Thus, 
there is no clearly identified consensus on good practice nor are there agreed quality 
measures. There is also the question of applicability across services; what may be good 
practice in opiate prescribing in a palliative oncology service is not likely to have broad 
relevance to controlling alcohol consumption in a shelter with the aim of engaging and 
retaining people in services. So, in appraising whether practice can be argued to be "good", 
we have drawn on indicators from other, relevant fields. For example, substance use 
services have long used harm reduction strategies and low threshold strategies to retain and 
engage people in the service. As this is accepted good practice, we have identified those 
papers who share such aims in considering palliative and end of life issues. In the case of the 
pain literature, there is some similarity in aiming to reduce harm but less consensus as to 
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how best to achieve this. Here there is also the question of good for whom? There appears 
to be an emphasis on strategies such as pill counting, short prescriptions and drug urine 
testing. This may be good practice within a framework of concern about drug diversion and 
“chemical coping” but not in terms of engagement of ‘hard to reach’ persons or as an 
effective means of managing pain. In the discussion below we draw out these themes to 
illustrate both practice examples and where the relevant debates lie.  
 
4.1  Good practice recommendations 
A number of recommendations3 for practice emerged from the literature. These have been 
presented below. However, consideration needs to be given the range of contexts within 
which they were developed.  
 
4.1.1  Managing pain 
In terms of good practice in relation to pain management, most of the papers were based 
on anecdotal evidence rather than strong empirical data. There were, however, some 
common recommendations from the diverse papers focusing on risk management and risk 
assessment: 
 
Not under prescribing for pain 
There was an acknowledgement in a number of papers that the most significant prescribing 
problem in relation to substance misuse is the persistent under treatment of pain in this 
population, driven by the inappropriate fear that opioids will be misused (Passik et al. 2009, 
Carmichael et al. 2016, Farnham 2012, Kirsh and Passik 2006, Knowlton et al. 2015, Kutzen 
2004, Lum 2003, Walsh and Broglio 2010, Williams et al. 2014). Indeed Farnham (2012) 
suggests uncertain prescribers may withhold medication and appropriate doses and this 
could lead to “aberrant, pseudo-addictive” behaviour in patients. Carmichael et al. (2016), 
for example, comment that opioid-use disorder in cancer is especially difficult to identify, in 
part because the problem may be formed in terms of “overtreatment” rather than abuse” 
(p77).   
 
Screening for substance use 
Identifying substance use was important for most authors with Arthur et al. (2016) 
suggesting that drug screening (within palliative care clinics) can be used to initiate an 
effective conversation about the potential dangers of drug behaviours. Most papers 
suggested universal screening using validated screening tools. Since distinguishing patients 
with potential or actual substance misuse issues was challenging, universal screening of 
patients was suggested by most papers as the best way to accurately capture this 
population. Urine drug testing was also recommended but generated debate about whether 
clinicians would have the expertise to manage a positive result (Carmichael et al. 2016). 
Urine drug testing appeared to be recommended as a secondary screening tool to monitor 
ongoing compliance to opioid therapy. A number of papers recommended screening family 
members too and assessing for potential drug diversion (Barclay et al. 2014, Krashin et al. 
2015, Tan et al. 2015). 
 
Screening for risk factors for substance use 
                                                     
3 These are recommendations from the evidence and not those from the research team. 
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Krashin et al. (2015) also suggested assessing for validated risk factors for developing 
problems with opioid use, for example, assessing for a history of substance use, including 
smoking, family history of substance misuse, history of childhood abuse including post-
traumatic stress disorder, and psychiatric comorbidities (anxiety, depression, personality 
disorder).  
 
Talking about substance use 
Underpinning most papers was the prerequisite requirement of effective and often direct 
communication (Arthur et al. 2016, Burton-MacLeod et al. 2008, Carmichael et al. 2016, 
Farnham 2012, Passik et al. 2012, Tan et al. 2015). Whether this happened, how to achieve 
it, and what sort of strategies would be helpful in managing direct conversations about 
substance misuse, was not a feature of the current literature. This literature also suggests 
that clinicians need to distinguish between pseudo-addictive behaviour(s), such as chemical 
coping and misuse of prescribed medication (Burton-MacLeod et al. 2008, Farnham 2012, 
Kwon et al. 2015). They may also need to distinguish between active users, individuals in 
methadone replacement therapy, and those in recovery (Kutzen 2004) and these require 
comprehensive, expert negotiations that many general clinicians may feel unequipped to 
undertake.  
 
Awareness of harm reduction approaches to substance use 
Underlying approaches to substance misuse were articulated by some authors, with harm 
reduction rather than abstinence seen as a more helpful approach (Burton-MacLeod et al. 
2008, Knowlton et al. 2015, Passik et al. 2012). Burton-MacLeod et al. (2008) suggests that 
the goal should be harm reduction because the person could be too emotionally/ 
psychologically and physically compromised to engage in abstinence programs.  There 
should also be liaison with local substance misuse teams to reach realistic goals (Farnham 
2012). 
 
Table 9 below summarises either the good practice identified to date in the evidence or 
recommendations for practice. 
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Table 9: Practice guidelines for pain management drawn from evidence 
 
Category Practice guidelines 
Universal screening for 
substance misuse 
Universal screening using a validated tool, for example, CAGE, 
AUDIT (screening tools for alcohol misuse), ORT, SOAP-SF 
(Screening tools for opioid and substance misuse).   
Ongoing screening and 
monitoring for 
substance use 
Consider random urine drug testing (UDT). 
Screen family members to avoid drug diversion. 
Observe for behaviours associated with addiction (requests for 
dose escalation, A&E visits, unscheduled clinic visits related to 
pain complaints, seeking early prescriptions, lost opioid 
prescriptions, approaching different prescribers, forged 
prescriptions).  
During follow- up visits use tools such as Pain Assessment and 
Documentation Tool (PADT) to assess levels of analgesia, the 
effect on capacity to self-care, adverse reactions 
Safety plans for 
identified patients with 
substance problems or 
high risk patients 
 
 
Involve and refer to specialist Multi-disciplinary Team (MDT) 
support that may include psychiatric/ psychological, or drug 
rehabilitation services.  
Written opioid agreements with expectations rules and 
consequences. 
Consider supervised medicines administration. 
Use one prescriber. 
Frequent outpatient appointments. 
Use slow release pain medication with limited supply of 
breakthrough painkillers that can be monitored. 
Pill count. 
Use non-opioid adjuvant medications4 whenever possible. 
Try non-pharmacological interventions (for example, relaxation 
& counselling). 
 
4.1.2  Homelessness and marginalised groups 
The literature identified in this REA did not contain any papers which specifically focussed 
on recommendations but several of the empirical papers proposed models which may have 
wider applicability.  
 
The Canadian literature (McNeil and Guriguis-Younger 2012a, 2012b, McNeil et al. 2014, 
McNeil et al. 2012a, 2012b, Podymov et al. 2006) examined models of innovative and 
responsive policies and practices emerging from work concerning homeless populations and 
end of life and palliative care. McNeil & Guirguis-Younger (2012b) looked at barriers to 
accessing end of life services and at the challenges that these populations present to service 
provision. Legal substances such as alcohol and over the counter medication did not appear 
                                                     
4 Adjuvant medications are used in conjunction with opioids to deal with specific symptoms, an 
example would be non-steroidal, anti-inflammatory drugs (NSAIDS).   
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to present barriers to accessing care. This appears to be due to a facility unique to Canada, 
the Managed Alcohol Programmes (MAPS). These are facilities which dispense alcohol 
hourly to prevent withdrawal. As the authors make clear, while an in depth discussion of 
these facilities in relation to end of life care was outside the scope of their work, the 
presence of such services were clearly perceived as providing stability and opening up 
access to services which made a significant difference.   
 
The place of supervised drug consumption (McNeil and Guriguis- Younger 2012a, 2012b) 
was discussed further in McNeil et al. (2014). This study discussed the need to develop such 
services to break down a significant barrier to access for some people including a "low-
threshold service", which explicitly aims to minimise barriers to access. Their proposal was 
that this approach could be piloted including facilities for supervised drug consumption.  
 
Although this strategy may be difficult to implement for a variety of reasons including legal 
constraints, the authors proposed that there were indications of the efficacy and cost 
effectiveness when barriers to access were addressed. They also found that drug use often 
declined or stabilised and the risk of over-prescribing reduced when greater trust was built 
leading to more accurate disclosure of consumption.  
 
Delivering services in settings that are familiar to substance using and homeless populations 
has been trialled in the UK as well as Canada (Hudson 2016). Despite a desire to support 
harm-reduction and a willingness to facilitate dying in a location of their choosing, some of 
the studies reviewed by Hudson showed that it was sometimes difficult, due to 
environmental and resource constraints, to fully achieve these goals (MacWilliams et al. 
2014, McNeil et al. 2012a, Webb 2015). 
 
Table 10: Practice guidelines  
 
Category Practice guidelines 
Environment(s) of care Deliver services in settings familiar to service users (e.g. "shelter 
based care", services in needle exchanges). 
Philosophy of care Use of a harm reduction rather than abstinence only model. 
Services should aim for low threshold strategies; those with 
minimum restrictions on service users’ normal patterns of 
behaviour.  
Service delivery 
 
 
 
 
Need for services to be flexible and responsive. Need for 
coordinated care with a case manager/case worker to prevent 
service users slipping through the gaps. Partnering of agencies 
to promote joint working. 
Safety plans for 
identified substance 
misuse or high risk 
patients 
Piloting of supervised consumption (of both alcohol and illicit 
drugs). 
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The literature suggests that the implementation of good practice within this population 
group is challenging for formalised care providers (Karus et al 2004; Dzul-Church et al 2010, 
Page et al 2012; McNeil et al 2012; McNeil and Guriguis-Younger 2012a, 2012b, McNeil et al 
2014, Hudson et al 2016). There is the underuse of primary and preventive services leading 
to greater use of emergency health provision, particularly for people living with 
homelessness or substance use or both (Hudson et al 2016). This makes advanced care-
planning challenging. There appears to be a lack of flexibility within service provision such as 
hospitals and hospices, leading patients with substance problems to self-discharge from 
hospital/healthcare settings due to restrictions on consumption of drugs or alcohol (McNeil 
and Guriguis-Younger 2012a). Engaging with self care and follow up after treatment is not a 
priority for this population. The challenges of maintaining treatment regimens and 
difficulties in attending planned appointments led to interruptions in care and again this 
makes formalised support challenging. From a patient perspective, previous experiences of 
mistrust, discrimination or limits on behaviour (for example not being able to drink alcohol 
or seek and consume illicit drugs) generated a reluctance and wariness to engage with 
health care (McNeil and Guriguis-Younger 2012a, McNeil et al 2012b). This was also often 
within the context of underlying mental health difficulties (Antoni et al 2012, Miovic and 
Block 2007). From a staff perspective there was distress and emotional burden from 
supporting patients/clients in spite of limited training in both end of life and substance use 
issues (McNeil et al 2012a, 2012b, McNeil and Guirguis-Younger 2012b).  
 
4.1.3  Alcohol literature 
The alcohol literature was sparse with only six papers included in this REA. The 
recommendations were similar to the pain management literature in terms of proposing 
universal screening for alcohol misuse (Dev et al. 2011, Kwon et al 2013b, Mercadante et al 
2015). Identifying alcohol misuse was important because it was associated with more 
distressing symptoms than those patients who did not misuse alcohol (Mercadante et al. 
2015), particularly in head and neck cancers (Kwon et al 2013b).  Identifying alcohol misuse 
was also important because it could indicate “chemical coping” as well as a potential 
underlying mental disorder (Dev et al. 2011).  Referring to specialist palliative care services 
was important since this was often overlooked by health professionals (Poonja et al 2014) as 
were issues related to alcohol withdrawal at the end of life (Irwin et al 2005).     
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Table 11: Practice guidelines related to the alcohol evidence 
 
Category Practice guidelines 
Universal screening for 
alcohol misuse 
Universally screening for alcohol misuse using a validated tool 
(For example, CAGE).   
Ongoing screening and 
monitoring for alcohol  
use 
Routine CAGE screening (younger patients are particularly at 
high risk of being CAGE positive).  
Frequent pain assessment.  
Assessment and treatment of alcohol withdrawal. 
Safety plans for 
identified patients with 
alcohol problems or 
high risk patients 
 
 
Assess for mental disorders. 
Involve and refer to specialist Multi-disciplinary team support 
that may include psychiatric/ psychological, or drug 
rehabilitation services.  
Frequent review of symptom distress. 
 
4.2  Challenges for care responses 
 
There were two broad sets of challenges identified in the literature which may affect the 
implementation of the practice guidelines above: 
 
1. Achieving safe and effective pain management within the context of an individual’s 
ongoing substance use.  
2. Managing the "lifestyle factors" that may be associated with substance use. This 
latter category encompasses behaviours and a range of anxieties and experiences 
that the person brings to service contact. The latter challenges may also involve 
families, friends and acquaintances who present behaviour that is difficult to manage 
and impacts on others.  
 
In terms of services used, what the literature shows is that substance users are likely to 
under-utilise preventive or primary care services (Hudson 2016, MacWilliams et al. 2014, 
McNeil et al. 2014), whilst over-utilising emergency services such as A & E. Some of the 
literature documented how substance users present to emergency services when acutely or 
seriously ill (French et al. 2000, Thakarar 2015, Wise-Harris 2017). It was reported that they 
have short admissions with premature self-discharge, and receive terminal diagnoses very 
late into the illness trajectory. This serves to mitigate against planning for death and high 
quality care (Song 2007a, McNeil 2012a, 2012b). 
 
The importance of effective and empathetic communication by clinicians/professionals was 
highlighted in the literature (Miovic and Block 2007; Hudson ; Mc Neil 2012a, 2012b, 2014, 
Burton-Macleod et al. 2008, Barclay et al. 2014, Arthur et al. 2016). In Miovic and Block's 
paper (2007: p 1672), the authors comment on the need for clinicians to listen; “A chance to 
be heard and understood, explore fears and concerns, mourn losses, articulate hopes and 
final wishes, and share the unique meaning that illness has for each individual”.  
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Morgan and Kochan (2008) propose that a flexible service response is central to meeting the 
complex challenges and needs that services are faced with. Similarly, MacWilliams et al. 
(2014) presented a case study and also interviewed six workers from a variety of settings 
including a primary care hospital-based team, a hospital-based palliative care team, a long- 
term residential programme for homeless men, a community-based homelessness nursing 
team, and a community-based team working with homeless people or those at risk of 
homelessness. The interviews explored issues of service provision and homelessness in 
relation to end of life care and showed the need for both flexibility and the importance of 
coordination by formalised care providers. They proposed that a case manager or case 
worker approach was the most useful approach.  
 
A paper by Mc Neil et al. (2014) report the findings of a small (n=13) qualitative study of 
residents in a specialist palliative HIV care facility which enabled supervised drug 
consumption. They found that residents were more willing to engage with palliative care 
services if they did not have to hide their drug use. McNeil and Guirguis-Younger (2012b) 
further discussed harm reduction in a policy oriented paper looking at the place of 
supervised drug consumption for illicit drug users in palliative care services. The authors 
comment that whilst much of the existing literature in this field stresses the need to 
understand the social context for substance use, this is seldom explored: “little attention 
has been paid to the ways in which the challenges posed by substance use may be 
compounded by homelessness” (2012b, pp 351). The barriers for people accessing services 
were competing priorities, for example, accessing illicit drugs, and a sense of exclusion from 
services. Participants described how continuing illicit substance use and the associated 
"income generating strategies" (2011, pp 353) led service users to "de-prioritise" health, 
decreasing routine or preventative contact with healthcare providers.  This, combined with 
a lack of trust and fear of judgement, and feelings of shame led to an avoidance of contact 
unless acutely ill. The policies and zero tolerance of end of life care providers presented 
significant barriers to access and many participants felt that the nature of end of life 
settings, "quiet, calm, serene" (p 354), meant that services would exclude people with 
substance problems based on anticipated behavioural issues.  
 
The two USA papers (Song et al., 2007a, 2007b) which explored the attitudes of homeless 
persons themselves to death, dying and end of life care, report on aspects of the findings of 
a qualitative study using in-depth interviews with 53 homeless people. The lack of the 
presence of a family or close friends assumed in most palliative care models was a space 
often filled by homelessness workers; a pattern also found in Webb's (2015) study. In the 
latter case, hostel staff described being with dying residents in their own time "that 
weekend I spent 17 hours at the hospital in my own time" (p 242) to avoid people dying 
alone and without a familiar face. They were also involved in vital practical matters such as 
arranging funerals. Song's work highlighted how important advance directives were to the 
homeless people they studied and how often it was hostel staff who were named as their 
surrogate decision makers rather than families or friends. Homeless, marginalised and, what 
Dzul-Church et al. (2010) termed “underserved patients”, include very large numbers of 
those with substance use problems or histories and lives characterised by trauma and 
deprivation. They present challenges to services but also frequently have the greatest range 
of unmet needs, which are compounded when seriously or terminally ill.  
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4.3  Directions for future research 
 
The following research implications have been drawn from this REA: 
 
1. There is a dearth of research evidence on this topic. More empirical research needs 
to be conducted exploring all aspects of problematic substance use and end of life 
care. Particularly in non-cancer contexts, prevalence studies, service provision and 
evaluative research.  
2. There is a lack of data from countries outside of North America. Comparative studies 
would be particularly beneficial to our understanding of the issues and health and 
social care responses within different cultural contexts. 
3. There were few prevalence studies. This is an area requiring more epidemiological 
research to provide a wider context for policy and practice development 
4. In terms of methodological inquiry, more quantitative approaches are needed to 
provide larger scale data on the experiences and needs of particular populations 
involved in service provision, e.g. palliative care social workers, community nurse 
provision.   
5. Further research is needed on conditions other than cancer that co-exist with 
substance use, both in terms of their prevalence and incidence, and also the health 
and social care responses available to people with experience of both substance use 
and life limiting illness. 
6. Research that identifies models of good practice in working with co-existing 
substance use and end of life conditions.  Such models of good practice need 
developing, piloting and evaluating for their effectiveness. 
7. Qualitative inquiry is required to establish the needs of family and friends of people 
with substance use problems at the end of life.  
8. Such qualitative inquiry should extend to patients’ voices which are under-
researched. 
9. Research must also include the experiences, views and attitudes of social and health 
care professionals in responding to the overlapping issues of substance use and end 
of life conditions.  
10. There was limited evidence found in relation to alcohol (for example, problematic 
alcohol consumption at the end of life and/or liver cirrhosis) and end of life care. 
Further work needs to be done in this area given it is the most commonly used 
substance after tobacco. 
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Section 5 - Conclusion 
 
This Rapid Evidence Assessment set out to explore current responses to, and models of 
practice for, people living with problematic substance use and end of life care conditions. It 
was quickly established that there is a dearth of research available on this topic and thus the 
focus of this review was broadened to identify what evidence was available, its focus, 
quality, and the gaps in the research evidence base.  
 
The resulting body of work comprised 60 papers, primarily from peer reviewed journals. It 
was quite disparate in focus, with a wide range of research populations, research questions 
and methodological choices. The available evidence resulted in three clear, but limited, 
groups of papers, those focussing on pain management and prescribing, those focussing on 
alcohol and end of life care and the third group including a body of work on homeless 
people with a small number of other papers including co-existing mental health or HIV-
related conditions.  
 
This is clearly an area of work where far more research is needed. The gaps identified are 
considerable and need to be filled in order to provide an evidence base on which to build 
future good policy and practice, both in the UK and internationally. 
 
This report not only sets out the findings of the REA but provides a systematic map of the 
existing evidence and its characteristics. It also provides a narrative on some of the 
recommendations and practice challenges which were embedded in the papers reviewed. 
These can help expand the debate on how best to ensure that the health inequalities faced 
by people with substance problems needing end of life care can be overcome.  
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